Argireline (topical) / Acetyl Hexapeptide-8
PeptideThe medical score (52) is lower than the community score (67), as clinical assessments place greater weight on limited skin penetration [s5, s6] and the industry-sponsored study landscape, whereas community users [c1, c2] rate subjectively perceptible effects — particularly in combination with other peptides — more favorably.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Argireline (Acetyl Hexapeptide-8) is the best-studied topical neuropeptide for expression lines — three controlled trials exist, including one RCT documenting ~49% anti-wrinkle efficacy at 4 weeks. The caveats are real: nearly all studies are industry-funded, skin penetration is under 0.2%, and independent replication is absent. Community consensus treats it as a subtle but legitimate tool, most effective when combined with Matrixyl — not a Botox replacement. Concerns about long-term muscle atrophy are theoretically plausible but scientifically unsupported given the minimal absorption.
Description
Synthetic hexapeptide (Acetyl Hexapeptide-8) for topical anti-aging applications; reduces expression lines through partial inhibition of the SNARE complex [s1, s2].
Argireline (Acetyl Hexapeptide-8, formerly also known as Acetyl Hexapeptide-3) is a synthetic hexapeptide derived from the N-terminal end of the SNAP-25 protein, a central component of the neuronal SNARE complex [s1, s3]. It was developed and introduced in 2002 by Lipotec (now part of Lubrizol) and has since been regarded as one of the most well-known and widely used cosmetic anti-wrinkle peptides [s12]. The peptide acts locally at the dermal neuromuscular junction by competitively inhibiting formation of the SNARE protein complex, thereby attenuating acetylcholine release and resulting in reduced muscle contraction [s1, s3, s4]. The mechanism is reversible and considerably weaker than that of botulinum toxin, as it is based on competitive inhibition rather than enzymatic cleavage [s3]. Skin penetration is limited: studies using human cadaver models and hairless guinea pigs demonstrated that less than 0.2% of the applied peptide penetrates the skin within 24 hours, with the active ingredient predominantly remaining in the stratum corneum [s5, s6]. Only 0.01% reached the epidermis; no detectable fraction reached the dermis or receptor fluid [s6]. Systemic toxicity is therefore considered unlikely [s6]. Clinical studies have documented wrinkle depth reductions of approximately 17–30% with periocular application over 28–30 days [s7]. A randomized, placebo-controlled study (Wang et al., 2013) demonstrated significant wrinkle reduction versus placebo after 4 weeks of twice-daily application [s12]. A further study with Argireline in combination with dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone showed 48.9% anti-wrinkle efficacy after 4 weeks [s8]. The combination with Leuphasyl (5% + 5%) achieved an average wrinkle depth reduction of 24.62%, with maximum values of 46.53% [s7]. Safety is considered established at cosmetically conventional concentrations...
Legal Status (DE)
Argireline is freely marketable in the EU as a cosmetic active ingredient (INCI: Acetyl Hexapeptide-8) under EU Cosmetics Regulation 1223/2009 and is not subject to authorization. It is neither a medicinal product nor a food supplement. The manufacturer is responsible for the safety assessment of the finished product in accordance with BfR requirements [s10, s11].
Mechanism of Action
Argireline is a biomimetic peptide structurally corresponding to the N-terminal end of SNAP-25 — one of the three SNARE proteins (together with syntaxin and VAMP/synaptobrevin) responsible for the fusion of synaptic vesicles with the presynaptic membrane [s1, s3]. Under normal conditions, SNAP-25 forms a stable heterotrimeric SNARE complex together with syntaxin and VAMP, enabling the docking and fusion of acetylcholine-containing vesicles at the neuromuscular endplate. This leads to acetylcholine release and consequent muscle contraction, which causes dynamic wrinkles upon repeated facial expressions [s1]. Argireline competes with endogenous SNAP-25 protein for binding sites within the SNARE complex. Through this competitive inhibition, formation of the functional trimeric complex is partially prevented, vesicular acetylcholine release is attenuated, and the contraction strength of the facial musculature is thereby reduced [s1, s3, s4]. In contrast to botulinum toxin type A, which proteolytically cleaves SNAP-25 and thus permanently inactivates it, Argireline acts exclusively through reversible, competitive displacement [s3]. The effect is therefore weaker and less sustained than Botox, but without systemic toxicity risk upon topical application [s3, s6]. The limited skin penetration (predominantly stratum corneum, <0.2% penetration after 24 h) is a relevant pharmacological factor that limits the intensity of action [s5, s6].
Dosing
Mimikfaltenreduktion (Monotherapie)
- Dose
- 2–10% in final formulation (serum/cream)
- Frequency
- 2× täglich
- Route
- topisch
- Duration
- Mindestens 4 Wochen; fortlaufend
- Timing
- Morning and evening after cleansing, before moisturizer
- With food
- optional
Synergistische Faltenreduktion (Kombination mit Leuphasyl)
- Dose
- 5% Argireline + 5% Leuphasyl in formulation
- Frequency
- 2× täglich
- Route
- topisch
- Duration
- 28 Tage
- Timing
- Morning and evening
- With food
- optional
Kombination mit Matrixyl (community-basiert)
- Dose
- 10% Argireline (e.g. The Ordinary) + separate Matrixyl product
- Frequency
- 1–2× täglich
- Route
- topisch
- Duration
- Fortlaufend
- Timing
- Applied in layers; Argireline first on cleansed skin
- With food
- optional
Concentrations of up to 10% have been used in clinical studies [s15]. The CIR safety assessment documents commercial concentrations of up to 0.005% in leave-on products as the typical market concentration [s10]. Higher concentrations are considered safe for topical application, as systemic absorption is minimal [s6]. No officially established upper limit exists under the EU Cosmetics Regulation for this active ingredient [s11].
Argireline should not be used simultaneously with strongly acidic formulations (pH < 4), as this may impair peptide stability. Microneedle pretreatment can significantly increase penetration [s14]. Effects are reversible and persist only with continued application.
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Milde lokale Hautreizung (Rötung, Trockenheit) Patch tests (48h) and 4-week application studies showed no significant irritation or allergic sensitization [s9]. Occasional reports in community sources [c4]. | selten | leicht |
| Temporäre Muskelsteifheit oder eingeschränkte Mimik (z. B. Augenbrauen) Individual user reports describe Botox-like restriction of eyebrow mobility with high-concentration application; not systematically documented clinically [c1, c3]. | selten | leicht |
| Theoretische Muskelatrophie bei Langzeitanwendung By analogy with botulinum toxin, it has been debated whether long-term SNARE inhibition promotes muscle atrophy. Evidence for this effect with topical argireline application is lacking; limited penetration (<0.2%) makes systemic effects unlikely [s5, s6]. | theoretisch | moderat |
| In-vitro antiproliferativer Effekt auf Fibroblasten An in vitro study demonstrated an antiproliferative effect on human cell lines, but only at extremely high concentrations far exceeding cosmetically used amounts. Clinical relevance is considered negligible [s13]. | theoretisch | leicht |
Contraindications
In cases of known contact allergy to peptide-containing cosmetics, a patch test should be performed prior to regular use [s9].
Compromised skin barrier may increase absorption; clinical data are lacking; caution is advised [s6].
Microneedle pretreatment significantly increases peptide penetration [s14]; this may potentiate unintended local neuromuscular effects, even though no direct safety concerns have been documented in studies.
Interactions
Synergistic
Combination of 5% Argireline + 5% Leuphasyl synergistically achieved 24.62% average wrinkle depth reduction, with maximum values up to 46.53% — superior to either component alone [s7].
Community experience and mechanistic considerations support synergy: Argireline reduces dynamic wrinkles via muscle relaxation, Matrixyl stimulates collagen synthesis for structural improvement [s7, c1, c2].
SNAP-8 is a structurally related peptide with potentially stronger SNARE inhibition. Combination theoretically synergistic, but no direct RCT data available [s3].
GHK-Cu and Argireline are frequently used in combined anti-aging formulations. GHK-Cu stimulates collagen synthesis and supports skin repair, while Argireline reduces dynamic wrinkles via muscle relaxation — both mechanisms are complementary.
Topical combination of Argireline with collagen peptides may represent a complementary anti-aging strategy. Clinical studies demonstrate firming effects of daily collagen supplementation, structurally complementing Argireline's neuromodulatory action.
Retinol and Argireline can be used synergistically in a skincare routine, as retinol promotes cell renewal and collagen production while Argireline reduces dynamic wrinkles. Experts recommend staggered application to minimize potential irritation.
Argireline works particularly well in combination with hyaluronic acid, which provides intensive hydration and plumps the skin surface, while Argireline neuromodulatorily reduces dynamic wrinkles. The combination addresses both volume-related and movement-related wrinkles.
Niacinamide supports the skin barrier and exerts anti-inflammatory effects, which can improve tolerability of peptide formulations. In combination with Argireline, a comprehensive anti-aging protocol with complementary mechanisms of action is achieved.
Caution
Acidic environment can impair Argireline peptide stability and reduce efficacy. Staggered application recommended.
Theoretical additive SNARE inhibition; not clinically investigated. The treating physician should be informed in case of concurrent Botox therapy.
Although the combination is generally possible, concurrent use of high-dose retinol with peptides such as Argireline may cause irritation. Experts advise staggered application (e.g., peptides in the morning, retinol in the evening).
Studies
Tier A — High Evidence
Outcome: Anti-wrinkle efficacy (combined formulation with AHP-8 + dipeptide + gluconolactone)
Effect Size: 48.9% total anti-wrinkle efficacy after 4 weeks; histological evidence of increased type I collagen synthesis [s8]
Outcome: Wrinkle reduction periorbital and forehead (fringe projection)
Effect Size: Significant reduction in wrinkle depth vs. placebo after 4 weeks, 2× daily application [s15]
Tier B — Moderate Evidence
Outcome: Wrinkle and scar prominence reduction
Effect Size: All 10 studies showed reductions; significance varied [s2]
Outcome: Clinical improvement in blepharospasm (adjunctive to BoNT)
Effect Size: Clinically perceptible improvement in pilot cohort [s16]
Tier C — Low Evidence
Outcome: Antiproliferative effect on human cell lines including fibroblasts
Effect Size: Antiproliferative effect only at very high, clinically irrelevant concentrations [s13]
Outcome: Percutaneous absorption of acetyl hexapeptide-3
Effect Size: <0.2% penetration after 24 h; peptide predominantly in stratum corneum [s5]
Community Evidence
Top reported benefits
- Visible reduction of expression lines (forehead, crow's feet) with regular use
- Particularly effective in combination with Matrixyl
- Rapidly visible effect (within a few weeks)
- Well tolerated, no irritation reported
- Cost-effective alternative to Botox for subtle effects
Top reported issues
- Effect as a standalone product often unconvincing; combination required
- Not a true Botox substitute; results considerably more subtle
- Results only present for as long as the product is applied (reversible)
- Isolated reports of restricted eyebrow mobility with high-concentration application
Isolated users report concerns regarding long-term muscle atrophy (analogous to Botox discussions) [c1, c4]. These concerns are not scientifically substantiated, as skin penetration is minimal [s5, s6]. Several users point out that clinically measured effects (microscopic wrinkle reduction) are barely perceptible to the naked eye and that expectations are often set too high [c1, c2].
Scientific Sources
- Acetyl hexapeptide-8 - Wikipedia (Acetyl hexapeptide-3 SNAP-25 SNARE mechanism)
Wikipedia contributors (2024). WikipediaCLink - Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics
Johnson W, Bergfeld WF, Belsito DV, et al. (2025). International Journal of Toxicology (CIR Expert Panel)ADOI - Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products
European Parliament, Council of the European Union (2009). Official Journal of the European UnionALink - Argireline Erfahrungen: Wirkung, Studien & Bewertung – Wang et al. 2013 Studie
Klow-Peptide Editorial (referencing Wang Y et al.) (2026). klow-peptide.comCLink - The study of cellular cytotoxicity of argireline – an anti-aging cosmetic ingredient
Authors per PubMed record (2014). PubMedCPMID:24644551 - Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment
Authors per ScienceDirect record (2013). ScienceDirect / Asian Journal of Pharmaceutical SciencesCDOI - The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study
Wang Y, et al. (2013). American Journal of Clinical Dermatology (referenced via cosmetic.science)ALink - Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy
Authors per PMC record (2016). PMCCLink - Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature
Authors not fully listed in search results (2025). Journal of Drugs in DermatologyBLink - SNAP-8: Anti-Wrinkle Cosmeceutical Peptide Guide – Peptide Protocol Wiki
Peptide Protocol Wiki contributors (2024). Peptide Protocol WikiCLink - Argireline (Acetyl Hexapeptide-3) – Complete Research Guide
PeptideDeck contributors (2024). PeptideDeckCLink - Skin permeability, a dismissed necessity for anti-wrinkle peptide performance
Mortazavi S, et al. (2022). International Journal of Cosmetic ScienceBDOI - A framework for the safety evaluation of peptides in cosmetics
Kraeling M, et al. (2024). PMC / Cosmetics Safety ReviewBLink - Anti-Wrinkle Peptides: SNAP-8, Argireline, Matrixyl, and Leuphasyl Compared – Evidence-Based Guide
Peptide Protocol Wiki contributors (2024). Peptide Protocol WikiCLink - The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies
Zhu W, et al. (2024). International Journal of Cosmetic ScienceADOI - Argireline Erfahrungen: Wirkung, Studien & Bewertung (2026) – klinische Verträglichkeitstests
Klow-Peptide Editorial (2026). klow-peptide.comCLink
Community Sources
Storage
Unopened
Store cool (15–25 °C), protected from light, and dry.
Opened
Use within 12 months of opening; keep container tightly closed. Do not store in the bathroom under high humidity conditions.
Notes
Peptides may denature at temperatures above 40 °C or below 0 °C. Manufacturer instructions regarding PAO (Period After Opening) should be observed.